Cardiol Therapeutics
CRDL
48 hedge funds and large institutions have $7.8M invested in Cardiol Therapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
26% more funds holding
Funds holding: 38 → 48 (+10)
0.67% more ownership
Funds ownership: 7.82% → 8.49% (+0.67%)
11% less capital invested
Capital invested by funds: $8.8M → $7.8M (-$992K)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$660K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$637K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$562K |
| 4 |
Goldman Sachs
New York
|
+$321K |
| 5 |
Two Sigma Investments
New York
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
-$771K |
| 2 |
LSA
Lion Street Advisors
Austin,
Texas
|
-$461K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$364K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$280K |
| 5 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$172K |
CRDL Hedge Fund Activity: Q3 2025 in Review
48 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q3 2025, worth a combined $7.8M — down 11% from $8.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CRDL positions and 7 closed out — a net gain of 10 holders — while 4 added to existing stakes and 13 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $660K. The largest seller was Tejara Capital, cutting an estimated $771K.
- 48 institutional investors held Cardiol Therapeutics (CRDL) as of Q3 2025, up from 38 in Q2 2025.
- Funds reported $7.8M of Cardiol Therapeutics stock for Q3 2025, down 11% quarter-over-quarter.
- 17 funds opened new Cardiol Therapeutics positions in Q3 2025 and 7 closed out, a net change of +10 holders.
- The largest Cardiol Therapeutics buyer in Q3 2025 was Marshall Wace, an estimated $660K added.
- The largest Cardiol Therapeutics seller in Q3 2025 was Tejara Capital, an estimated $771K sold.
Based on aggregated 13F filings for Q3 2025.